# Vir Biotechnology (VIR) — Earnings

VIR · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/vir/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | $0.47 |
| EPS estimate | $0.33 |
| EPS surprise | +41.31% |
| Revenue surprise | +75.85% |
| Revenue | $238.9M |
| Revenue estimate | $135.9M |
| Reported | Aug 5, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1706431/000162828026053549/vir-20260630.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/d7fb5707-974c-1345-414b-3f057b3cde77.html) |

Vir Biotechnology reported Q2 2026 results on August 5, 2026. It earned $0.47 per share, ahead of the $0.33 estimate by 41.31%. Revenue was $238.9 million against a $135.9 million consensus. A year earlier, in Q2 2025, Vir lost $0.80 per share on revenue of $1.2 million.

The quarter was Vir's first profit in the table since Q3 2022. In between came 14 straight quarterly losses, including $0.85 per share in Q1 2026. Annual losses per share were $4.59 in 2023, $3.82 in 2024 and $3.16 in 2025, on yearly revenue of $86.2 million, $74.3 million and $68.5 million. Quarterly revenue swung widely over that stretch, from $240,000 in Q3 2025 to $64.1 million in Q4 2025. The earliest rows look very different: Vir earned $3.92 per share in Q4 2021 and $3.85 in Q1 2022, on revenue of $812.7 million and $1.2 billion. Over the 20 quarters shown, Vir beat the EPS estimate 9 times.

Q3 results have come out between October 31 and November 5 in each of the past five years. That points to early November 2026 for the next report, which will show whether the profit holds for a second quarter.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 5, 2026 | $0.33 | $0.47 | 41.31% | $135.9M | $238.9M |
| Q1 2026 | May 6, 2026 | −$0.10 | −$0.85 | -790.05% | $55.5M | — |
| Q4 2025 | Feb 23, 2026 | −$0.49 | −$0.31 | 36.88% | $19.9M | $64.1M |
| Q3 2025 | Nov 5, 2025 | −$0.84 | −$1.17 | -38.64% | $2.0M | $240,000.00 |
| Q2 2025 | Aug 6, 2025 | −$0.72 | −$0.80 | -10.67% | $2.7M | $1.2M |
| Q1 2025 | May 7, 2025 | −$0.84 | −$0.88 | -5.30% | $8.6M | $3.0M |
| Q4 2024 | Feb 26, 2025 | −$0.87 | −$0.76 | 12.86% | $8.2M | $12.4M |
| Q3 2024 | Oct 31, 2024 | −$1.05 | −$1.56 | -48.22% | $5.5M | $2.4M |
| Q2 2024 | Aug 1, 2024 | −$0.90 | −$1.02 | -13.97% | $7.5M | $3.1M |
| Q1 2024 | May 2, 2024 | −$1.05 | −$0.48 | 54.35% | $11.7M | $56.4M |
| Q4 2023 | Feb 22, 2024 | −$1.01 | −$0.86 | 14.67% | $11.2M | $16.8M |
| Q3 2023 | Nov 2, 2023 | −$1.21 | −$1.22 | -1.09% | $8.7M | $2.6M |
| Q2 2023 | Aug 3, 2023 | −$1.20 | −$1.45 | -20.50% | $22.4M | $3.8M |
| Q1 2023 | May 4, 2023 | −$0.87 | −$1.06 | -21.20% | $50.1M | $63.0M |
| Q4 2022 | Feb 23, 2023 | −$0.35 | −$0.76 | -118.71% | $149.6M | $49.4M |
| Q3 2022 | Nov 3, 2022 | −$0.51 | $1.30 | 355.91% | $114.2M | $374.6M |
| Q2 2022 | Aug 9, 2022 | $0.33 | −$0.58 | -276.40% | $200.7M | — |
| Q1 2022 | May 5, 2022 | $3.78 | $3.85 | 1.85% | $811.0M | $1.2B |
| Q4 2021 | Feb 24, 2022 | $2.63 | $3.92 | 49.26% | $623.0M | $812.7M |
| Q3 2021 | Nov 4, 2021 | −$0.05 | $0.82 | 1826.32% | $138.3M | $103.6M |

## Frequently Asked Questions

### When did Vir Biotechnology (VIR) last report earnings?

Vir Biotechnology last reported on Aug 5, 2026, covering fiscal Q2 2026.

### Did VIR beat earnings estimates?

Yes. Vir Biotechnology reported EPS of $0.47 for Q2 2026 against a $0.33 estimate — a 41.31% beat.

### How much revenue did VIR report last quarter?

Vir Biotechnology reported $238.9M in revenue for Q2 2026, against a consensus estimate of $135.9M.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).